The type-2 inflammation pathway’s signaling role for IL-4 and IL-13 identifies IL-4R alpha as a potential target for individuals who exhibit aberrant type-2 inflammatory responses.

Alpha-2 receptors are also located postsynaptically in vascular smooth muscle and in the endothelial wall, which can mediate nitric oxide release and cause vasodilation.

It blocks the alpha 1 receptor of IL-13 but not the alpha 2 receptor. It's thought that this property gives it a regulatory effect favorable to its efficacy.